Cargando…
COVID-19: The Potential Treatment of Pulmonary Fibrosis Associated with SARS-CoV-2 Infection
In December 2019, a novel coronavirus, SARS-CoV-2, appeared, causing a wide range of symptoms, mainly respiratory infection. In March 2020, the World Health Organization (WHO) declared Coronavirus Disease 2019 (COVID-19) a pandemic, therefore the efforts of scientists around the world are focused on...
Autores principales: | Lechowicz, Kacper, Drożdżal, Sylwester, Machaj, Filip, Rosik, Jakub, Szostak, Bartosz, Zegan-Barańska, Małgorzata, Biernawska, Jowita, Dabrowski, Wojciech, Rotter, Iwona, Kotfis, Katarzyna |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7356800/ https://www.ncbi.nlm.nih.gov/pubmed/32575380 http://dx.doi.org/10.3390/jcm9061917 |
Ejemplares similares
-
COVID-19: Pain Management in Patients with SARS-CoV-2 Infection—Molecular Mechanisms, Challenges, and Perspectives
por: Drożdżal, Sylwester, et al.
Publicado: (2020) -
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment
por: Drożdżal, Sylwester, et al.
Publicado: (2021) -
FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy
por: Drożdżal, Sylwester, et al.
Publicado: (2020) -
Peripheral Blood Lymphocyte Subsets (CD4(+), CD8(+) T Cells, NK Cells) in Patients with Cardiovascular and Neurological Complications after Carotid Endarterectomy
por: Kotfis, Katarzyna, et al.
Publicado: (2015) -
Kidney damage from nonsteroidal anti‐inflammatory drugs—Myth or truth? Review of selected literature
por: Drożdżal, Sylwester, et al.
Publicado: (2021)